Nasdaq · Biotech stocks database

ANL — Adlai Nortye Group Ltd.

ANL (Adlai Nortye Group Ltd.) stock: $10.28, $662.0M market cap, $60.9M cash, $627.4M EV, $692.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

We initially focused primarily on generic pharmaceuticals and polypeptide intermediate, until 2016 when our founders, Mr. Yang Lu and Mr. Donghui Yang, led our strategic transition to become a R&D-driven pharmaceutical company, focusing on the discovery and development of innovative cancer therapies.

Source: 20-F FY2025 via SEC EDGAR

Share price

$10.28

Market cap

$662.0M

Cash

$60.9M

Enterprise value

$627.4M

Balance sheet

Cash	$60.9M
Debt	$26.3M
Net cash	$34.6M
Enterprise value	$627.4M
Basic shares	64.4M shares
Fully diluted shares	67.4M shares
Fully diluted market cap	$692.5M
Cash per share	$0.95
Quarterly burn	$13.0M
Cash runway	4.7 quarters

Cash figures as of 2024-12-31. Database snapshot: 2026-11-07.

Share structure

Common

64.4M

Pre-funded warrants

0.0M

Options

1.5M

RSUs

1.4M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

67.4M

Cap table as of 2026-06-30.

Price history

Loading ANL daily closes…

Loading price history…

Next catalyst

AN4005 · Now - Nov 30, 2026 · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDNow - Nov 30, 2026 Now	AN4005 Expansion cohorts clinical update	Not disclosed	Expansion cohorts	2026 (SITC meeting)
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	AN0025 ARTEMIS Phase II in rectal cancer	Phase 2	rectal cancer	1H 2027
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	AN9025 Phase Ia QD/QW in RAS-mutant solid tumors	Phase 1a	RAS-mutant solid tumors	1H 2027
GUIDEDEst. Sep 30, 2027 in 8 mo half midpoint	AN4035 Phase I in CEACAM5-enriched RAS-addicted solid tumors	Phase 1	CEACAM5-enriched RAS-addicted solid tumors	2H 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Cormorant Asset Management	3,978,229	+1,080,372	2.34%	2026-08-14
Perceptive Advisors	1,793,190	+1,793,190	0.32%	2026-08-14
Casdin Capital	1,250,000	+711,539	0.72%	2026-08-14
ADAR1 Capital Management	1,017,805	+899,896	0.55%	2026-08-14
Braidwell LP	795,214	+795,214	0.34%	2026-08-14
DAFNA Capital	239,553	+239,553	0.53%	2026-08-14
Ikarian Capital	33,899	no change	0.06%	2026-08-14
Stonepine Capital	24,257	+24,257	0.21%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

ANL — Adlai Nortye Group Ltd. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Specialist fund holders

Latest news

ANL — Adlai Nortye Group Ltd.